Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi

PHASE3CompletedINTERVENTIONAL
Enrollment

161

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

June 30, 2019

Study Completion Date

September 30, 2020

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

iGlarLixi

Dose is titrated to achieve fasting normoglycemia

DRUG

Insulin Glargine

In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.

DRUG

Metformin

Dose is titrated to 2000 mg daily or maximal tolerated dose

BEHAVIORAL

Lifestyle therapy

Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving

Trial Locations (8)

T2T 5C7

University of Calgary, Calgary

M4G 3E8

LMC, Burlington

N1R 7L6

Joanne Liutkus, Cambridge

L8N 3Z5

McMaster University, Hamilton

N6A 4V2

St. Joseph's Hospital, London

N6G 2M1

Western University, London

K1Y 4E9

The Ottawa Hospital, Ottawa

H4A 3J1

McGill University, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Population Health Research Institute

OTHER